{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:09:49Z","timestamp":1767982189706,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T00:00:00Z","timestamp":1354579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00702-012-0925-5","type":"journal-article","created":{"date-parts":[[2012,12,3]],"date-time":"2012-12-03T06:32:32Z","timestamp":1354516352000},"page":"1069-1081","source":"Crossref","is-referenced-by-count":50,"title":["Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson\u2019s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER"],"prefix":"10.1007","volume":"120","author":[{"given":"Peter A.","family":"LeWitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Surmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,4]]},"reference":[{"key":"925_CR1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1474-4422(09)70225-X","volume":"8","author":"A Antonini","year":"2009","unstructured":"Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH (2009) A reassessment of risks and benefits of dopamine agonists in Parkinson\u2019s disease. Lancet Neurol 8:929\u2013937","journal-title":"Lancet Neurol"},{"key":"925_CR2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1358\/dot.2010.46.7.1463530","volume":"46","author":"B Boroojerdi","year":"2010","unstructured":"Boroojerdi B, Wolff HM, Braun M, Scheller DK (2010) Rotigotine transdermal patch for the treatment of Parkinson\u2019s disease and restless legs syndrome. Drugs Today (Barc) 46:483\u2013505","journal-title":"Drugs Today (Barc)"},{"key":"925_CR3","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH, SP513 investigators (2007) Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398\u20132404","journal-title":"Mov Disord"},{"key":"925_CR4","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22:2409\u20132417","journal-title":"Mov Disord"},{"key":"925_CR5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044\u20131053","journal-title":"Arch Neurol"},{"key":"925_CR6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.64.5.676","volume":"64","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Watts RL, Martin W, Boroojerdi B (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 64:676\u2013682","journal-title":"Arch Neurol"},{"issue":"2 Suppl 1","key":"925_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1212\/WNL.65.2_suppl_1.S3","volume":"65","author":"P Jenner","year":"2005","unstructured":"Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson\u2019s disease. Neurology 65(2 Suppl 1):3\u20135","journal-title":"Neurology"},{"key":"925_CR8","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","volume":"359","author":"PA LeWitt","year":"2008","unstructured":"LeWitt PA (2008) Levodopa for the treatment of Parkinson\u2019s disease. N Engl J Med 359:2468\u20132476","journal-title":"N Engl J Med"},{"key":"925_CR9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/B978-0-12-374105-9.00234-3","volume-title":"Encyclopedia of movement disorders","author":"P LeWitt","year":"2010","unstructured":"LeWitt P (2010) Dopaminergic agonists in Parkinson\u2019s disease. In: Kompoliti VM (ed) Encyclopedia of movement disorders. Academic press, Oxford, pp 332\u2013336"},{"key":"925_CR10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 68:1262\u20131267","journal-title":"Neurology"},{"key":"925_CR11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","volume":"20","author":"JC M\u00f6ller","year":"2005","unstructured":"M\u00f6ller JC, Oertel WH, K\u00f6ster J, Pezzoli G, Provinciali L (2005) Long-term efficacy and safety of pramipexole in advanced Parkinson\u2019s disease: results from a European multicenter trial. Mov Disord 20:602\u2013610","journal-title":"Mov Disord"},{"key":"925_CR12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1353-8020(01)00024-4","volume":"8","author":"JG Nutt","year":"2001","unstructured":"Nutt JG (2001) Motor fluctuations and dyskinesia in Parkinson\u2019s disease. Parkinsonism Relat Disord 8:101\u2013108","journal-title":"Parkinsonism Relat Disord"},{"key":"925_CR13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"2","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Nat Clin Pract Neurol 2:382\u2013392","journal-title":"Nat Clin Pract Neurol"},{"issue":"Suppl 1","key":"925_CR14","first-page":"S280","volume":"24","author":"R Pahwa","year":"2009","unstructured":"Pahwa R, Poewe WH, Lyons KE, Boroojerdi B (2009) Changes in early morning motor status following adjunctive treatment of advanced Parkinson\u2019s disease with rotigotine transdermal system in two large, placebo-controlled trials (PREFER and CLEOPATRA-PD). Mov Disord 24(Suppl 1):S280","journal-title":"Mov Disord"},{"key":"925_CR15","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284:1931\u20131938","journal-title":"JAMA"},{"key":"925_CR16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","volume":"60","author":"Parkinson Study Group","year":"2003","unstructured":"Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson\u2019s disease. Arch Neurol 60:1721\u20131728","journal-title":"Arch Neurol"},{"key":"925_CR17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","volume":"66","author":"Parkinson Study Group CALM Cohort Investigators","year":"2009","unstructured":"Parkinson Study Group CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563\u2013570","journal-title":"Arch Neurol"},{"key":"925_CR18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.clinthera.2008.05.007","volume":"30","author":"DQ Pham","year":"2008","unstructured":"Pham DQ, Nogid A (2008) Rotigotine transdermal system for the treatment of Parkinson\u2019s disease. Clin Ther 30:813\u2013824","journal-title":"Clin Ther"},{"key":"925_CR19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513\u2013520","journal-title":"Lancet Neurol"},{"key":"925_CR20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/14656560902746041","volume":"10","author":"O Rascol","year":"2009","unstructured":"Rascol O, Perez-Lloret S (2009) Rotigotine transdermal delivery for the treatment of Parkinson\u2019s disease. Expert Opin Pharmacother 10:677\u2013691","journal-title":"Expert Opin Pharmacother"},{"key":"925_CR21","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"925_CR22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90\u201399","journal-title":"Mov Disord"},{"key":"925_CR23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"RL Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272\u2013276","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-012-0925-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0925-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T18:52:01Z","timestamp":1553626321000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-012-0925-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,4]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1007\/s00702-012-0925-5","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,4]]}}}